Brokerages Set Tabula Rasa HealthCare Inc (TRHC) Price Target at $82.44

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has received an average recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $82.44.

Several research analysts have issued reports on TRHC shares. Zacks Investment Research lowered Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Saturday, November 10th. BidaskClub lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 15th. Cantor Fitzgerald restated a “buy” rating and set a $99.00 target price on shares of Tabula Rasa HealthCare in a report on Tuesday, November 6th. Chardan Capital increased their target price on Tabula Rasa HealthCare from $77.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Robert W. Baird restated a “buy” rating and set a $70.00 target price on shares of Tabula Rasa HealthCare in a report on Wednesday, August 8th.

Tabula Rasa HealthCare stock opened at $65.33 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.49 and a quick ratio of 0.46. Tabula Rasa HealthCare has a 52-week low of $27.25 and a 52-week high of $91.16. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -1,633.25, a P/E/G ratio of 6.04 and a beta of 2.58.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.07. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The firm had revenue of $54.42 million during the quarter, compared to analyst estimates of $52.87 million. During the same period in the prior year, the company posted $0.08 earnings per share. The business’s revenue for the quarter was up 66.3% compared to the same quarter last year. Equities analysts anticipate that Tabula Rasa HealthCare will post 0.42 EPS for the current fiscal year.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton bought 7,500 shares of the firm’s stock in a transaction dated Monday, November 12th. The shares were bought at an average price of $65.00 per share, for a total transaction of $487,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $85.98, for a total value of $687,840.00. The disclosure for this sale can be found here. Insiders have sold 48,000 shares of company stock worth $3,638,560 in the last 90 days. Company insiders own 14.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in TRHC. Comerica Bank bought a new position in Tabula Rasa HealthCare in the second quarter valued at about $947,000. Citadel Advisors LLC boosted its holdings in Tabula Rasa HealthCare by 47.0% in the second quarter. Citadel Advisors LLC now owns 8,855 shares of the company’s stock valued at $565,000 after acquiring an additional 2,832 shares during the last quarter. Pitcairn Co. bought a new position in Tabula Rasa HealthCare in the second quarter valued at about $285,000. Rhumbline Advisers boosted its holdings in Tabula Rasa HealthCare by 34.5% in the second quarter. Rhumbline Advisers now owns 36,119 shares of the company’s stock valued at $2,305,000 after acquiring an additional 9,272 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in Tabula Rasa HealthCare by 29.7% in the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock valued at $135,288,000 after acquiring an additional 484,979 shares during the last quarter. Institutional investors own 78.17% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Read More: No Load Funds

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply